These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32119654)

  • 1. Main concepts on bioequivalence and biosimilarity in the Chilean legislation, and current controversies on drug interchangeability.
    Stojanova J; Lutz M; Lazcano G; Arancibia M
    Medwave; 2020 Feb; 20(2):e7825. PubMed ID: 32119654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some thoughts on drug interchangeability.
    Chow SC; Song F; Chen M
    J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
    Rivera VM
    Neurol Ther; 2019 Dec; 8(2):177-184. PubMed ID: 31313222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The implementation of the bioequivalence certification policy in Chile: An analysis of market authorization data.
    Kaplan WA; Cárdenas J; Mansilla C; Tobar T; Wirtz VJ
    PLoS One; 2019; 14(5):e0217334. PubMed ID: 31141565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical and regulatory considerations in assessments of interchangeability of biological drug products.
    Tóthfalusi L; Endrényi L; Chow SC
    Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S5-11. PubMed ID: 24832831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing bioequivalence and drug interchangeability.
    Chen M; Chow SC
    J Biopharm Stat; 2017; 27(2):272-281. PubMed ID: 27936343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interchangeability of biological products in the Brazilian Unified National Health System (SUS): the main regulatory challenges].
    Ferreira Neto PTP; Nunes PHC; Vargas MA
    Cad Saude Publica; 2019; 35(10):e00053519. PubMed ID: 31618379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial steps in the regulation of generic biological drugs: a comparison of U.S. and Canadian regimes.
    Szeto KJ; Wolanski M
    Food Drug Law J; 2012; 67(2):131-41, i. PubMed ID: 24620416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From bioequivalence to biosimilars: How much do regulators dare?
    Weise M
    Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the interchangeability of biologic drug products.
    Endrenyi L; Chang C; Chow SC; Tothfalusi L
    Stat Med; 2013 Feb; 32(3):434-41. PubMed ID: 22911936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scientific considerations for assessing biosimilar products.
    Chow SC; Wang J; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):370-81. PubMed ID: 22933240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Bioequivalence to Biosimilarity: The Rise of a Novel Regulatory Framework.
    Karalis VD
    Drug Res (Stuttg); 2016 Jan; 66(1):1-6. PubMed ID: 25894088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical evaluation of the scaled criterion for drug interchangeability.
    Li J; Chow SC
    J Biopharm Stat; 2017; 27(2):282-292. PubMed ID: 27937059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comprehensive Overview on Biosimilars.
    Kadam V; Bagde S; Karpe M; Kadam V
    Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biosimilars, the journey has begun].
    Martos-Rosa A; Martínez-de la Plata JE; Morales-Molina JA; Fayet-Pérez A; Acosta-Robles PJ
    Farm Hosp; 2015 Mar; 39(2):114-7. PubMed ID: 25817091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
    O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
    Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biosimilars in oncology: a therapeutic alternative to the reference products?].
    Ludwig WD; Dicheva S
    Z Gastroenterol; 2016 Nov; 54(11):1223-1229. PubMed ID: 27723912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
    Verbeeck RK; Kanfer I; Walker RB
    Eur J Pharm Sci; 2006 May; 28(1-2):1-6. PubMed ID: 16413762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms.
    Meredith PA
    Curr Med Res Opin; 2009 Sep; 25(9):2179-89. PubMed ID: 19601710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.